China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market uptake of the company’s PD-1 inhibitor Tyvyt (sintilimab injection), as well as increased sales of other products.
Upcoming Product Launches
Innovent is poised for further growth with the expected market launch of three anti-tumor drugs in 2025. Among the six innovative products set for launch, Daboyue (taletrectinib) is an ROS1 tyrosine kinase inhibitor targeting lung cancer. The company also plans to launch EGFR inhibitor Aoyixin (limertinib) and Jaypirca (pirtobrutinib), a BTK inhibitor for blood cancer. These launches are expected to bolster Innovent’s position in the oncology market.
Future Outlook
With strong Q4 sales and a robust pipeline of innovative products, Innovent Biologics is well-positioned for continued growth in 2025. The upcoming launches highlight the company’s commitment to advancing treatments for various cancers, further solidifying its presence in the global biopharmaceutical market.-Fineline Info & Tech
